Longevity biotech Junevity has emerged with $10 million in seed funding to advances its work to develop “cell reset” therapies aimed at extending human healthspan and lifespan. The San Francisco-based startup is targeting age-related diseases by leveraging AI and large-scale human data to identify and target transcription factors – genes that regulate cellular health. https://longevity.technology/news/junevity-emerges-with-10m-to-reset-cells-to-a-healthy-state/